Lung cancer: New drug shows promise in lab mice
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A new category of drug brakes the growth of treatment-resistant lung cancer among lab mice, according to a study published on Thursday in the science journal Nature.
The new type could add powerfully to a small family of drugs called epidermal growth factor receptor (EPFR) inhibitors, say its finders.
It tackles mutations in a specific form of lung tumour that often becomes hardened to frontline treatment, according to the study.
The molecule, identified by Pasi Janne and colleagues at the Dana Farber Cancer Institute in Boston, stymied the growth of lung cancer among batches of genetically modified mice.
Their work focusses on so-called non-small-cell lung tumours, which account for 70 to 80 percent of bronchial cancers.
These tumours carry mutations that cause a particular protein, the EGFR, to be permanently activated.
The frontline drugs for tackling non-small-cell tumours are Iressa and Tarceva. They are designed to block the "switch," but secondary mutations often emerge that lead to drug resistance.
Much work remains to determine if the new compound can be a therapy for humans, says the study.
"Obviously these are very early days with respect to the possible use of these compounds in patients - we still have much to learn about their possible liabilities," said co-author Michael Eck in a press release.
"But I am optimistic that our approach is correct and that it will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide who development resistance to Iressa and Tarceva every year."
ri/jj
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments